Northern Treatment
Advisory Group

What treatments will NTAG consider?

The Northern Treatment Advisory Group has a remit to consider drug and medical devices that are prescribale. It is anticipated that the majority of treatment appraisals undertaken will relate to pharmaceutical treatments. NTAG will not consider specialised commissioning treatments as they fall under the remit of NHS England. In addition, NTAG will not consider treatments for indications that have been appraised by NICE or for which NICE is due to issue guidance within the next 6 months.

Priority will be given to treatment appraisals where there is a clear rationale and advantages from a single regional approach. Additionally, NTAG will prioritise treatments that are considered to be expensive as these often give rise to variations in access.

It may also be preferable for NTAG to consider new drugs that represent a first-in-class therapeutic agent, or a new and important new indication for an existing drug, so that precedent can be established for any subsequent similar drugs and for the same indication(s).

In the absence of significant changes to the licensed indications of existing drugs NTAG would not consider less novel treatments such as ‘me-too’ drugs, new presentations, formulations or methods of delivery, combination products where both drugs have previously been available separately, and single enantiomers or metabolites of an existing drug.

One of the aims of NTAG is to reduce variations in access and use of treatments. Therefore if significant variations already exist or are not justified or desirable on clinical, therapeutic (including safety) or equitable grounds, it may again be preferable for NTAG to consider the treatment.

In case of doubt please contact the professional secretary via nuth.nyrdtc.rxsupp@nhs.net or via the contact form on the website: www.ntag.nhs.uk

Should this medicine or medical device be referred to the Northern Treatment Advisory Group?



NTAG also has remit to consider medical devices which are prescribable in the Drug Tariff.

NTAG will only consider those medical devices with the potential for a medium to high cost impact, offer an alternative option to a medicine in the current treatment pathway, with the potential for variations in access across the ICS, and where there may be high patient demand/potential for large numbers of patients being prescribed the device.